Osmotica Pharmaceuticals (OSMT) is primed for a buyout

Osmotica Pharmaceuticals (OSMT) has created eye drops RVL-1201 (non-surgical) solution for drooping eye lid condition. This condition occurs due to partial or complete dysfunction of the muscles.

Currently, patients have to undergo complex medical surgery to fix drooping eye condition. Eye drops/drug will activate Mueller muscle to fix drooping eye lid condition. Few analysts have a price target of $9-$10.

Why OSMT stock is primed for a buyout

Last week, David F Burgstahler, a major owner of Osmotica Pharmaceuticals and a director of the company, recently disposed of 4,936,926 shares of the company. The disposals took place at $0.00 per share, on November 20, 2020. Burgstahler still owns 16,763,859 shares of the company. Burgstahler operates out of New York, NY.

Institutional investors increase positions

  • Avista Capital Partners III GP, L.P. bumps its position to 25.2% of OSMT

Burried in the SEC file they released yesterday,

 Item 4. Purpose of Transaction. (page 7) : The Company disclosed that this review will also include the initiation of a process for the sale of the Company.

Osmotica Pharmaceuticals (OSMT) is primed for a buyout
Screenshot of SEC file / fintel.io

Note that this is good timing for acquisition as they had an approved PDUFA on 7/16 and have one coming up for 12/29 for arbaclofen.


Where to put $5 right now

STOP BUYING STOCKS RIGHT NOW … And start taking a serious look at options, the investment vehicle that is driving stocks like Tesla and Apple to historically unprecedented highs.

Subscribe below to get insight into options trades!

Default image
Tim Rolle
Investor of 6 years and Managing Editor of Money Midnight, a news outlet focused on highly profitable investment ideas and bold underground research.
Articles: 113

Newsletter Updates

Enter your email address below to subscribe to our newsletter